• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
    • ATPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • RIPK2 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assay – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Targeting Oncogenic Ras: Hope on the Horizon

by katie.lowery / Friday, 22 August 2014 / Published in Emerging Targets

Mutations in the small GTPase K-Ras are one of the most common known molecular drivers of cancer; approximately 30% of all human cancers contain the oncogenic mutant of K-Ras. Tumors containing oncogenic K-Ras are generally less responsive to therapies than other biological subtypes and consequently, patients with these tumors tend to have poorer outcomes.  Directly targeting oncogenic K-Ras with small molecules has proven particularly difficult for a number of reasons.

To start with, the oncogenic mutations inactivate the GTPase activity of the protein, locking it into the GTP bound, activated state.  So the traditional approach of inhibiting enzymatic activity is not an option.  And even preventing binding of GDP to Ras with a competitive inhibitor is extremely challenging because of its extremely high binding affinity and high cellular concentration.  Efforts to block communication with downstream effectors by disrupting protein-protein interactions have been met with limited success.  In the hopes of overcoming these hurdles, two recent studies, one from a group led by Kenneth Westover at UT southwestern and the other from Kevan Shokat and colleagues at UCSF, propose novel approaches to targeting oncogenic Ras.

Two structurally dynamic loops, switch I and switch II, make up a key portion of the binding interface between K-Ras and numerous downstream effectors.  Both the Westover and Shokat groups hypothesized that, to be successful, direct-acting K-Ras inhibitors must alter the conformation of switch I and/or II to the point that it becomes incapable of transmitting activating signals.  Both groups were successful in achieving this, though apparently through different mechanisms.

Both groups targeted the G12C oncogenic mutation of Ras, which avoids disruption of signaling by the wild type protein.  Westover and colleagues used a rational design approach to develop an inhibitor, SML-8-73-1, that binds covalently to G12C in the guanine nucleotide site.  Their high resolution structure of the K-ras G12C/SML-8-73-1 complex showed K-Ras in an inactive conformation, and in situ proteomic-based chemical profiling showed that the compound was highly selective for K-Ras G12C over other small GTPases.   The group used a chemosensor-based assay to measure the reaction rates between K-Ras G12C and SML in the presence of GTP and GDP.  The results demonstrate that SML is able to efficiently compete, and indeed successfully overcome GTP and GDP in the battle for binding to the guanine nucleotide site.

Targeting the same G12C mutant of Ras, Shokat and colleagues used a structure guided approach to develop compounds that switch the nucleotide binding preference from GTP to GDP, which leads to the accumulation of Ras in the inactive state.  Interestingly, though specific for the G12C mutant, their compounds do not bind at the guanine nucleotide binding site, but instead at an allosteric pocket located beneath the effector binding switch II region that was not apparent in previous structures of Ras.  Like the covalent G12C binding inhibitor, SML-8-73-1, the Shokat group’s compounds render K-Ras in the open conformation which is inactive with downstream effectors.

While continued chemical optimization and future assessment of the compounds in vivo is needed, Shokat and colleagues report that intitial evaluation of their compounds in lung cancer cell lines suggest allele–specific impairment of K-Ras function.  The two groups believe that their findings can serve as a starting point for drug discovery efforts targeting K-Ras and hope that, eventually, the approach may be generalized to other GTPases.

A surprising aspect of these parallel discoveries is how much we apparently did not know about one of the most intensively studies proteins in all of biology, and a small one (20 KDa) at that.  One lesson may be that leveraging conformational dynamics can yield druggable sites on seemingly intractable protein targets.

Tagged under: Transcreener GDP Assay

What you can read next

Validation of a GEF Inhibitor in Murine Models of Major Osteolytic Diseases
BellBrook Labs Awarded NIH Grant to Develop a High Throughput cGAS Assay for Cancer and Autoimmune Disease Drug Discovery
SARM1 Causes Axonal Death
SARM1 Forefronts Research into Major Neurological Diseases

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • PARP1 as a Hero vs Villain

    Is PARP1 a Hero or Villain?

    Not counting histones, PARP1 [Poly(ADP-ribose) ...
  • Ongoing Puzzle of c-SRC in Cancer Treatment

    Advancements in The Ongoing Puzzle to Understand c-SRC

    Nearly a half-century ago, sequences from the R...
  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2023 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP